MAPT and Alzheimer disease: A broad variety of technologies (including neuroimaging and cerebrospinal fluid [CSF] analysis) is currently used to study the potential prognostic meaning of well‐known signs of AD pathology (amyloid, tau and neurodegeneration), both in isolation and combined in multimodal models [12].